Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...
| मुख्य लेखकों: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| स्वरूप: | Journal article |
| प्रकाशित: |
Frontiers Media
2018
|
| _version_ | 1826300566642360320 |
|---|---|
| author | Westwood, S Baird, AL Hye, A Ashton, NJ Nevado-Holgado, AJ Anand, SN Liu, B Newby, D Bazenet, C Kiddle, SJ Ward, M Newton, B Desai, K Hehir, C Zanette, M Galimberti, D Parnetti, L Lleó, A Baker, S Narayan, VA Van Der Flier, WM Scheltens, P Teunissen, CE Visser, PJ Lovestone, S |
| author_facet | Westwood, S Baird, AL Hye, A Ashton, NJ Nevado-Holgado, AJ Anand, SN Liu, B Newby, D Bazenet, C Kiddle, SJ Ward, M Newton, B Desai, K Hehir, C Zanette, M Galimberti, D Parnetti, L Lleó, A Baker, S Narayan, VA Van Der Flier, WM Scheltens, P Teunissen, CE Visser, PJ Lovestone, S |
| author_sort | Westwood, S |
| collection | OXFORD |
| description | <strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong>Objective:</strong> To discover a plasma proteomic signature associated with CSF and PET measures of AD pathology. <strong>Methods:</strong> Liquid chromatography-tandem mass spectrometry (LC-MS/MS) based proteomics were performed in plasma from participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD, recruited to the Amsterdam Dementia Cohort, stratified by CSF Tau/Aβ42 (n = 50). Technical replication and independent validation were performed by immunoassay in plasma from SCD, MCI, and AD participants recruited to the Amsterdam Dementia Cohort with CSF measures (n = 100), MCI participants enrolled in the GE067-005 study with [18F]-Flutemetamol PET amyloid measures (n = 173), and AD, MCI and cognitively healthy participants from the EMIF 500 study with CSF Aβ42 measurements (n = 494). <strong>Results:</strong> 25 discovery proteins were nominally associated with CSF Tau/Aβ42 (P < 0.05) with associations of ficolin-2 (FCN2), apolipoprotein C-IV and fibrinogen β chain confirmed by immunoassay (P < 0.05). In the GE067-005 cohort, FCN2 was nominally associated with PET amyloid (P < 0.05) replicating the association with CSF Tau/Aβ42. There were nominally significant associations of complement component 3 with PET amyloid, and apolipoprotein(a), apolipoprotein A-I, ceruloplasmin, and PPY with MCI conversion to AD (all P < 0.05). In the EMIF 500 cohort FCN2 was trending toward a significant relationship with CSF Aβ42 (P ≈ 0.05), while both A1AT and clusterin were nominally significantly associated with CSF Aβ42 (both P < 0.05). <strong>Conclusion:</strong> Associations of plasma proteins with multiple measures of AD pathology and progression are demonstrated. To our knowledge this is the first study to report an association of FCN2 with AD pathology. Further testing of the proteins in larger independent cohorts will be important. |
| first_indexed | 2024-03-07T05:19:07Z |
| format | Journal article |
| id | oxford-uuid:de43f1a4-816a-4c8f-a94b-e5673f645422 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T05:19:07Z |
| publishDate | 2018 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:de43f1a4-816a-4c8f-a94b-e5673f6454222022-03-27T09:31:18ZPlasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan resultJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:de43f1a4-816a-4c8f-a94b-e5673f645422Symplectic Elements at OxfordFrontiers Media2018Westwood, SBaird, ALHye, AAshton, NJNevado-Holgado, AJAnand, SNLiu, BNewby, DBazenet, CKiddle, SJWard, MNewton, BDesai, KHehir, CZanette, MGalimberti, DParnetti, LLleó, ABaker, SNarayan, VAVan Der Flier, WMScheltens, PTeunissen, CEVisser, PJLovestone, S<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong>Objective:</strong> To discover a plasma proteomic signature associated with CSF and PET measures of AD pathology. <strong>Methods:</strong> Liquid chromatography-tandem mass spectrometry (LC-MS/MS) based proteomics were performed in plasma from participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD, recruited to the Amsterdam Dementia Cohort, stratified by CSF Tau/Aβ42 (n = 50). Technical replication and independent validation were performed by immunoassay in plasma from SCD, MCI, and AD participants recruited to the Amsterdam Dementia Cohort with CSF measures (n = 100), MCI participants enrolled in the GE067-005 study with [18F]-Flutemetamol PET amyloid measures (n = 173), and AD, MCI and cognitively healthy participants from the EMIF 500 study with CSF Aβ42 measurements (n = 494). <strong>Results:</strong> 25 discovery proteins were nominally associated with CSF Tau/Aβ42 (P < 0.05) with associations of ficolin-2 (FCN2), apolipoprotein C-IV and fibrinogen β chain confirmed by immunoassay (P < 0.05). In the GE067-005 cohort, FCN2 was nominally associated with PET amyloid (P < 0.05) replicating the association with CSF Tau/Aβ42. There were nominally significant associations of complement component 3 with PET amyloid, and apolipoprotein(a), apolipoprotein A-I, ceruloplasmin, and PPY with MCI conversion to AD (all P < 0.05). In the EMIF 500 cohort FCN2 was trending toward a significant relationship with CSF Aβ42 (P ≈ 0.05), while both A1AT and clusterin were nominally significantly associated with CSF Aβ42 (both P < 0.05). <strong>Conclusion:</strong> Associations of plasma proteins with multiple measures of AD pathology and progression are demonstrated. To our knowledge this is the first study to report an association of FCN2 with AD pathology. Further testing of the proteins in larger independent cohorts will be important. |
| spellingShingle | Westwood, S Baird, AL Hye, A Ashton, NJ Nevado-Holgado, AJ Anand, SN Liu, B Newby, D Bazenet, C Kiddle, SJ Ward, M Newton, B Desai, K Hehir, C Zanette, M Galimberti, D Parnetti, L Lleó, A Baker, S Narayan, VA Van Der Flier, WM Scheltens, P Teunissen, CE Visser, PJ Lovestone, S Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result |
| title | Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result |
| title_full | Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result |
| title_fullStr | Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result |
| title_full_unstemmed | Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result |
| title_short | Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result |
| title_sort | plasma protein biomarkers for the prediction of csf amyloid and tau and 18f flutemetamol pet scan result |
| work_keys_str_mv | AT westwoods plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT bairdal plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT hyea plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT ashtonnj plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT nevadoholgadoaj plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT anandsn plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT liub plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT newbyd plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT bazenetc plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT kiddlesj plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT wardm plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT newtonb plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT desaik plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT hehirc plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT zanettem plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT galimbertid plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT parnettil plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT lleoa plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT bakers plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT narayanva plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT vanderflierwm plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT scheltensp plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT teunissence plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT visserpj plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult AT lovestones plasmaproteinbiomarkersforthepredictionofcsfamyloidandtauand18fflutemetamolpetscanresult |